• Mario Cavagna, João Carlos Mantese, Gilberto da Costa Freitas, Artur Dzik, Jonathas Borges Soares, Yaron Hameiry, Vicente Mario Izzo, and José Aristodemo Pinotti.
• Human Reproduction Division, Hospital Pérola Byington, Rua Viradouro 58, CEP 04538-110 São Paulo, SP, Brazil. cavagna@hotmail.com
• Sao Paulo Med J. 2005 Nov 3; 123 (6): 295297295-7.

Context And ObjectiveAdministration of a gonadotropin-releasing hormone (GnRH) agonist at the preovulatory phase is an option for triggering ovulation in assisted reproductive technology cycles. The aim of this work was to investigate the pattern of prolactin secretion after the administration of a single dose of GnRH-agonist at the preovulatory phase.Design And SettingDescriptive study at a tertiary referral center.ParticipantsFifteen normally ovulating patients undergoing ovarian stimulation for intrauterine insemination were studied.MethodsOvarian stimulation was carried out using human menopausal gonadotropin (intramuscular 75 IU daily). When at least one follicle reached 17 mm (observed echographically), 0.5 mg of buserelin acetate was administered. Blood samples were taken to determine prolactin concentrations, at the time of agonist injection and 4, 8, 12, 24 and 48 hours later.ResultsA statistically significant increase in serum levels of prolactin was observed 4, 8 and 12 hours after GnRH-agonist administration, with a peak at 8 hours.ConclusionThe administration of a single dose of GnRH-agonist at the preovulatory phase in patients undergoing ovarian stimulation performed with human menopausal gonadotropin causes a significant increase in serum prolactin levels.

15 keywords...

hide…